Glycosylation: a hallmark of cancer?

Glycoconjugate Journal

Volumn 34, Issue 2, 2017, Pages 147-156

  Vajaria, Bhairavi N ^a   Patel, Prabhudas S ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Cancer; E cadherin; EGFR; Glycosylation; Hallmarks; Matrix metalloproteinases; p53

Indexed keywords

CELL ADHESION MOLECULE; GLYCAN; GLYCOSIDASE; GLYCOSYLTRANSFERASE; MUCIN; SELECTIN; TUMOR ANTIGEN; TUMOR MARKER; UVOMORULIN; POLYSACCHARIDE;

APOPTOSIS; CANCER CELL; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; DISEASE ASSOCIATION; EARLY CANCER DIAGNOSIS; FUCOSYLATION; GLYCOSYLATION; HUMAN; MALIGNANT NEOPLASM; METASTASIS; REVIEW; SIALYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VASCULAR ENDOTHELIUM; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; GLYCOSYLATION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; POLYSACCHARIDES;

EID: 85006151127     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-016-9755-2     Document Type: Review

References (100)

1. Reis, C.A., Osorio, H., Silva, L., Gomes, C., David, L.: Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 63, 322–329 (2010)
2. Kam, R.K., Poon, T.C.: The potentials of glycomics in biomarker discovery. Clin. Proteomics. 4, 67–79 (2008)
3. Munkley, J., Elliott, D.J.: Hallmarks of glycosylation in cancer. Oncotarget. 7, 35478–35489 (2016)
4. Karavani, V.P.: Aiming the sweet side of cancer: aberrant glycosylation as possible target for personalized medicine. Cancer Lett. 352, 101–112 (2014)
5. Pinho, S.S., Reis, C.A.: Glycosylation in cancer: mechanism and clinical implications. Nat. Rev. Cancer. 15, 540–555 (2015)
6. Shah, M.H., Telang, S.D., Shah, P.M., Patel, P.S.: Tissue and serum α2-3-and α2-6-linkage specific sialylation changes in oral carcinogenesis. Glycoconj. J. 25, 279–290 (2008)
7. Shah, M.H., Telang, S.D., Raval, G.N., Shah, P.M., Patel, P.S.: Serum fucosylation changes in oral cancer and oral precancerous conditions. Cancer. 113, 336–346 (2008)
8. Bhanushree, R.: Clinical relevance of serum total sialic acid in oral leukoplakia and oral squamous cell carcinoma – a randomized study. Global Journal For Research Analysis. 4, 17–19 (2015)
9. Kadam, C.Y., Katkam, R.V., Suryakar, A.N., Kumbar, K.M., Kadam, D.P.: Biochemical markers in oral cancer. Biomed. Res. 22, 76–80 (2011)
10. Sawney, H., Kumar, C.A.: Correlation of serum biomarkers (TSA & LSA) and epithelial dysplasia in early diagnosis of oral precancer and oral cancer. Cancer Biomark. 10, 43–49 (2011)
11. Joshi, M., Patil, R.: Estimation and comparative study of serum total sialic acid levels as tumor markers in oral cancer and precancer. J. Cancer Res. Ther. 6, 263–266 (2010)
12. Raval, G.N., Parekh, L.J., Patel, D.D., Jha, F.P., Sainger, R.N., Patel, P.S.: Clinical usefulness of alterations in sialic acid, sialyl transferase and sialoproteins in breast cancer. Indian J. Clin. Biochem. 19, 60–71 (2004)
13. Ozturk, L.K., Emekli-Alturfan, E., Kasikcy, E., Demir, G., Yarat, A.: Salivary total sialic acid levels increase in breast cancer patients: a preliminary study. Med. Chem. 7, 443–447 (2011)
14. Patel, P.S., Rawal, G.N., Balar, D.B.: Importance of serum sialic acid and lactate dehydrogenase in diagnosis and treatment monitoring of cervical cancer patients. Gynecol. Oncol. 50, 294–299 (1993)
15. Patel, P.S., Adhvaryu, S.G., Balar, D.B., Parikh, B.J., Shah, P.M.: Clinical application of serum levels of sialic acid, fucose and seromucoid fraction as tumor markers in human leukemias. Anticancer Res. 14, 747–751 (1994)
16. Patel, P.S., Adhvaryu, S.G., Balar, D.B.: Serum glycoconjugates in patients with anemia and myeloid leukemia. Tumori. 74, 639–634 (1988)
17. Vajaria, B.N., Patel, K.R., Begum, R., et al.: Salivary Glyco-sialylation changes monitors oral carcinogenesis. Glycoconj. J. 31, 649–659 (2014)
18. Cylwik, B., Chrostek, L., Szmitkowski, M.: Diagnostic value of total and lipid-bound sialic acid in malignancies. Pol. Merkur. Lekarski. 19, 237–241 (2005)
19. Suer Gokmen, S., Kazezoglu, C., Tabakoglu, E., Altıay, G., Gungor, O., Ture, M.: Serum total sialic acid levels in lung cancer patients of different histological types with and no extrapulmonary metastases. Turk. J. Biochem. 29, 262–267 (2004)
20. Siddhartha, Bhandary, S., Kumari, S., Shetty, R., Babu, S., Shetty, S.: Status of serum sialic acid, antioxidant and lipid peroxidation in head and neck cancer patients. Res. J. Pharm., Biol. Chem. Sci. 2, 1–5 (2011)
21. Cebi, A., Mert, H., Mert, N.: Evaluation of some tumor markers, acute phase proteins, sialic acid and lipid bound sialic acid before and after chemotherapy in patients with stomach cancer. Medical Science and Discovery. 3, 22–27 (2016)
22. Paskowska, A., Borbec, H., Semczuk, A., Cybulski, M.: Sialic acid concentration in serum and tissue of endometrial cancer patients. Eur. J. Obstet. Gynecol. Reprod. Biol. 76, 211–215 (1998)
23. Dall’Olio, F., Chiricolo, M., D’Errico, A., Gruppioni, E., Altimari, A., Fiorentino, M., et al.: Expression of beta-galactoside alpha2, 6 sialyl transferase and of alpha2, 6-sialylated glycoconjugates in normal human liver, hepatocarcinoma and cirrhosis. Glycobiology. 14, 39–49 (2004)
24. Yamamoto, H., Saito, H., Kaneko, Y., et al.: Alpha 2, 3-sialyl transferase mRNA and alpha2, 3-linked glycoprotein sialylation are increased in malignant gliomas. Brain Res. 755, 175–179 (1997)
25. Vajaria, B.N., Patel, K.R., Begum, R., Shah, F.D., Patel, J.B., Joshi, G.M., et al.: Significance of glycosyltransferases: ST3GAL1, FUT3, FUT5 and FUT6 transcripts in oral cancer. Glycobiology Insights. 4, 7–14 (2014)
26. Reuters, G., Struwe, R., Feigel, J., Brede, R., Bumm, P., Schauer, R.: Analysis of carbohydrate composition and sialidase activity in oral secretions of patients with tumors in the upper aerodigestive tract. Eur. Arch. Otorhinolaryngol. 249, 5–11 (1992)
27. Sonmez, H., Suer, S., Gungor, Z., Baloglu, H., Kokoglu, E.: Tissue and serum sialidase levels in breast cancer. Cancer Lett. 136, 75–78 (1999)
28. Miyagi, T., Yamaguchi, K.: Mammalian sialidases: physiological and pathological roles in cellular functions. Glycobiology. 22, 880–896 (2012)
29. Lopes-Morales, D., Velasquez-Marquez, N., Valenzueka, O., Santos-Lopez, G., Reyes-Levya, J., Vallejo-Ruiz, V.: Enhanced sialyltransferases transcription in cervical epithelial neoplasia. Investig. Clin. 50, 45–53 (2009)
30. Wang, P.H., Li, Y.F., Juang, C.M., Lee, Y.R., Chao, H.T., Ng, H.T., et al.: Expression of sialyl transferase family members in cervix squamous cell carcinoma correlates with lymph node metastasis. Gynecol. Oncol. 86, 45–52 (2002)
31. Wang, P.H., Li, Y.F., Juang, C.M., Lee, Y.R., Chao, H.T., Tsai, Y.C.: Altered mRNA expression of sialyltransferase in squamous cell carcinoma of the cervix. Gynecol. Oncol. 2001(83), 121–127 (2001)
32. Schneider, F., Kemmner, W., Haensch, W., Franke, G., Gretschel, S., Karsten, U., et al.: Overexpression of sialyltransferase CMP-sialic acid: Galbeta1,3GalNAc-R alpha6-sialyltransferase is related to poor survival in human colorectal carcinoma. Cancer Res. 61, 4605–4611 (2001)
33. Picco, G., Julien, S., Brockhausen, I., Beatson, R., Antonopoulos, A., Haslam, S., et al.: Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 20, 1241–1250 (2010)
34. Recchi, M.A., Hebbar, M., Hornez, L., Harduin-Lepers, A., Peyrat, J.P., Delannoy, P.: Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 58, 4066–4070 (1998)
35. Videira, P.A., Correia, M., Malagolini, N., Crespo, H.J., Ligeiro, D., Calais, F., et al.: ST3Gal I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer. 9, 357 (2009)
36. Wang, P.H., Lee, W.L., Juang, C.M., Yang, Y.H., Lo, W.H., Lai, C.R.: Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecol. Oncol. 99, 631–639 (2005)
37. Natoni, A., Macauley, M.S., O’Dwyer, M.E.: Targeting selectins and their ligands in cancer. Front Oncol. 6, 93 (2016)
38. Trinchera, M., Malagolini, N., Chiricolo, M., Santini, D., Minni, F., Caretti, A., et al.: The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach. Int. J. Biochem. Cell Biol. 43, 130–139 (2011)
39. Hanski, C., Klussmann, E., Wang, J., Böhm, C., Ogorek, D., Hanski, M.L., et al.: Fucosyltransferase III and sialyl-Lex expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue. Glycoconj. J. 13, 727–733 (1996)
40. Ogawa, J.I., Inoue, H., Koide, S.: α −2,3 sialyltrasferase type 3 N and α-1,3fucosyl transferase type VII are related to sialyl Lewis (x) synthesis and patients survival from lung carcinoma. Cancer. 79, 1678–1685 (1997)
41. Yan, X., Lin, Y., Liu, S., Aziz, F., Yan, Q.: Fucosyltranferase IV (FUT4) as an effective biomarker for the diagnosis of breast cancer. Biomed. Pharmacother. 70, 299–304 (2015)
42. Carvalho, A.S., Harduin-Lepers, A., Magalhaes, A., Machado, E., Mendes, N., Costa, L.T.: Differential expression of α-2, 3-sialyltransferases and α-1, 3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells. Int. J. Biochem. Cell Biol. 42, 80–89 (2010)
43. Petretti, T., Kemmner, W., Schulze, B., Schlag, P.M.: Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases. Gut. 46, 359–366 (2000)
44. Kudo, T., Ikehara, Y., Togayachi, A., et al.: Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Lab. Investig. 78, 797–811 (1998)
45. Thompson, S., Turner, G.A.: Elevated levels of abnormally-fucosylated haptoglobins in cancer sera. Br. J. Cancer. 56, 605–610 (1987)
46. Shirahama, T., Ikoma, M., Muramatsu, T., Kayajima, T., Ohi, Y., Tsushima, T.: The binding site for fucose-binding proteins of Lotus tetragonolobus is a prognostic marker for transitional cell carcinoma of the human urinary bladder. Cancer. 72, 1329–1334 (1993)
47. Wang, J.W., Ambros, R.A., Weber, P.B., Rosana, T.G.: Fucosyltransferase and alpha-L-fucosidase activities and fucose levels in normal and malignant endometrial tissue. Cancer Res. 55, 3654–3658 (1995)
48. Abdel-Aleem, H., Ahmed, A., Sabra, A.M., Zakhari, M., Soliman, M., Hamed, H.: Serum alpha L-fucosidase enzyme activity in ovarian and other female genital tract tumors. Int. J. Gynaecol. Obstet. 55, 273–279 (1996)
49. Vajaria, B.N., Patel, K.R., Begum, R., Shah, F.D., Patel, J.B., Shukla, S.N., et al.: Evaluation of serum and salivary total sialic acid and alpha-L-fucosidase in patients with oral precancerous condition and oral cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 115, 764–771 (2013)
50. Giardina, M.G., Matarazzo, M., Morante, R., Lucariello, A., Varriale, A., Guardasole, V.: Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma:a prospective study of patients with cirrhosis. Cancer. 83, 2468–2474 (1998)
51. Ayude, D., Paez De La Cadena, M., Martinez-Zorzano, V.S., Fernadez-Briera, A., Rodriguez-Berrocal, F.J.: Preoperative serum alpha-L-fucosidase activity as a prognostic marker in colorectal cancer. Oncology. 64, 36–45 (2003)
52. Wei, X., Wang, S., Rui, J.: The value of serum alpha-L-fucosidase activity in the diagnosis of primary liver cancer. Zhonghua Zhong Liu Za Zhi. 22, 148–150 (2000)
53. Shetty, V., Hafner, J., Shah, P., Nickens, Z., Philip, R.: Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clin. Proteomics. 9, 10 (2012)
54. Kumar, S., Saxena, M., Srinivas, K., Singh, V.K.: Fucose: a biomarkers in grading of oral cancer. Natl. J. Maxillofac. Surg. 6, 176–179 (2015)
55. Rai, N.P., Anekar, J., Shankara, S., Divakar, D.D., Al KAlheraif, A.A., Ramakrishnaih, R., et al.: Comparison of serum fucose levels in leukoplakia and oral cancer patients. Asian Pac. J. Cancer Prev. 16, 7497–7500 (2015)
56. Manjula, S., Monteiro, F., Rao Aroor, A., Rao, S., Annaswamy, R., Rao, A.: Assessment of serum L-fucose in brain tumor cases. Ann. Indian Acad. Neurol. 13, 33–36 (2010)
57. Wang, L., Liu, Y., Wu, L., Sun, X.L.: Sialyltransferase inhibition and recent advances. Biochim. Biophys. Acta. 1864, 143–153 (2016)
58. Aoyagi, Y., Isemura, M., Yosizawa, Z., Suzuki, Y., Sekine, C., Onto, T., et al.: Fucosylation of serum alpha fetoprotein in patients with primary hepatocellular carcinoma. Biochim. Biophys. Acta. 830, 217–223 (1996)
59. Noda, T., Miyoshi, E., Kitada, T., Nakahara, S., Gao, C.X., Honke, K., et al.: The enzymatic basis for the conversion of non-fucosylated to fucosylated alpha-fetoprotein by acyclic retinoid treatment in human hepatoma cells: activation of alpha 1,6 fucosyltransferase. Tumor Biol. 23, 202–211 (2002)
60. Miyoshi, E., Uozumi, N., Sobajima, T., Takamatsu, S., Kamada, Y.: Roles of fucosyltransferases in cancer phenotypes. Book: Glycosignals in cancer: mechanisms of malignant phenotypes, pp. 3–16. Springer, Japan (2016)
61. De Leoz, M.L., Young, L.J.T., An, H.J., Kronewitter, S.R., Kim, J., Miyamoto, S.: High mannose glycans are elevated during breast cancer progression. Mol. Cell. Proteomics. 10, M110–002717 (2011)
62. Hauselmann, I., Borsig, L.: Altered tumor cell glycosylation promotes metastasis. Front. Oncol. 4, 28 (2014)
63. Hakomori, S.: Tumor associated carbohydrate antigens defining tumor malignancy: basis for development of anticancer vaccines. Adv. Exp. Med. Biol. 491, 369–402 (2001)
64. Shah, M.H., Sainger, R.N., Telang, S.D., Pancholi, G.H., Shukla, S.N., Patel, P.S.: E-cadherin truncation and sialyl Lewis-X overexpression in oral squamous cell carcinoma and oral precancerous conditions. Neoplasma. 56, 40–47 (2009)
65. Roy, R., Yang, J., Moses, M.A.: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287–5297 (2009)
66. Gialeli, C., Theocharis, A.D., Karamanos, N.K.: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278, 16–27 (2011)
67. You, T.K., Kim, K.M., Noh, S.J., Bae, J.S., Jang, K.Y., Chung, J.Y.: Expressions of E-cadherin, cortactin and MMP-9 in pseudoepitheliomatous hyperplasia and squamous cell carcinoma of the head and neck: their relationships with clinicopathologic factors and prognostic implication. Korean J. Pathol. 46, 331–340 (2012)
68. Zhou, J., Tao, D., Xu, Q., Gao, Z., Tang, D.: Expression of E-cadherin and vimentin in oral squamous cell carcinoma. Int. J. Clin. Exp. Pathol. 8, 3150–3154 (2015)
69. Sridevi, U., Jain, A., Nagalaxmi, V., Kumar, U.V., Goyal, S.: Expression of E-cadherin in normal oral mucosa, in oral precancerous lesions and in oral carcinomas. European J. Dent. 9, 364–372 (2015)
70. Cavallaro, U., Christofori, G.: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer. 4, 118–132 (2004)
71. Specenier, P., Brouwer, A.: Matrix metalloproteinases in head and neck cancer. World Journal of Surgical Medical and Radiation Oncology. 4, 18–27 (2015)
72. Zheng, W.Y., Zhang, D.T., Yang, S.Y., Li, H.: Elevated MMP-9 expression correlates with advanced stages of oral cancer and is linked to poor clinical outcomes. J. Oral Maxillofac. Surg. 73, 2334–2342 (2015)
73. Singh, R.D., Haridas, N., Patel, J.B., Shah, F.D., Shukla, S.N., Shah, P.M., et al.: Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer. Indian J. Clin. Biochem. 25, 250–259 (2010)
74. Vajaria, B.N., Patel, K.R., Begum, R., Shah, F.D., Patel, J.B., Joshi, G.M.: Clinical significance of salivary matrix metalloproteinase-9 in oral precancerous conditions and oral cancer. Cancers Review. 1, 33–44 (2014)
75. Shah, F.D., Shukla, S.N., Shukla, P.M., Shukla, H.N., Patel, P.S.: Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J. Cancer. 46, 194–202 (2009)
76. Bull, C., Stoel, B.A., den Brok, M.H., Adema, G.J.: Sialic acids sweeten’s a tumor’s life. Cancer Res. 74, 3199–3204 (2014)
77. Pidone Ribeiro, F.A., Noguti, J., Fujimaya Oshima, C.T., Araki Ribeiro, D.: Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach. Anticancer Res. 34, 1547–1552 (2014)
78. Wilding, J., Vousden, K.H., Soutter, W.P., McCrea, P.D., Del Buano, R., Pignatelli, M., et al.: E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res. 56, 5285–5292 (1996)
79. Zeng, F., Harris, R.C.: Epidermal growth factor receptor from gene organization to bed side. Semin. Cell Dev. Biol. 28, 2–11 (2014)
80. Bremm, A., Walch, A., Fuchs, M., Mages, J., Duyster, J., Keller, G., et al.: Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. Cancer Res. 68, 707–714 (2008)
81. Reddy, P., Liu, L., Ren, C., Lindgren, P., Boman, K., Shen, Y., et al.: Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Mol. Endocrinol. 19, 2564–2578 (2005)
82. Gavard, J., Gutkind, J.S.: A molecular cross talk between E-cadherin and EGFR signaling networks. EGFR signaling networks in cancer therapy. In EGFR Signaling Networks in Cancer Therapy. Humana Press. 131–146 (2008)
83. Lu, Z., Ghosh, S., Wang, Z., Hunter, T.: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 4, 499–515 (2003)
84. Thiery, J.P.: Epithelial–mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15, 740–746 (2003)
85. Andl, C.D., Rustgi, A.K.: No one-way street: cross-talk between E-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol. Ther. 4, 35–38 (2005)
86. Bae, G.Y., Choi, S.J., Lee, J.S., Jo, J., Lee, J., Kim, J., et al.: Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget. 4, 2512–2522 (2013)
87. Buonato, M., Lazzara, M.J.: ERK1/2 blockade prevents EMT in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res. 74, 309–319 (2014)
88. Sato, F., Shimada, Y., Watanabe, G., Uchida, S., Makino, T., Imamura, M.: Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br. J. Cancer. 80, 1366–1372 (1999)
89. Theodoropoulos, G.E., Karafoka, E., Papailiou, J.G., Stamopoulos, P., Zambirinis, C.P., Bramis, K., et al.: P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Anticancer Res. 29, 785–791 (2009)
90. Okawa, T., Michaylira, C.Z., Kalabis, J., Stairs, D.B., Nakagawa, H., Andl, C., et al.: The functional interplay between EGFR overexpression, hTERT activation and p53 mutation in oesophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion and differentiation. Genes Dev. 21, 2788–2803 (2007)
91. Pais-Costa, S.R., Farah, J.F., Artigiani-Neto, R., Martins, S.J., Goldenberg, A.: Evaluation of P53, E-cadherin, cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma. Arq. Bras. Cir. Dig. 27, 126–132 (2014)
92. Ramaswamy, S., Duraisamy, S., Barbashov, S., Kawano, T., Kharbanda, S., Kufe, D.: The MUC1 and galectin-3 oncoproteins functions in micro RNA-dependent regulatory loop. Mol. Cell. 27, 992–1004 (2007)
93. Pochampalli, M.R., el Bejjani, R.M., Schroeder, J.A.: MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene. 26, 1693–1701 (2007)
94. Kufe, D.W.: Mucins in cancer: functions, prognosis and therapy. Nat. Rev. Cancer. 9, 874–885 (2009)
95. Ahmad, R., Raina, D., Joshin, M.D., Kawano, T., Ren, J., Kharbanda, S., et al.: MUC1-C oncoprotein functions as a direct activator of the NF-κB p65 transcription factor. Cancer Res. 69, 7013–7021 (2009)
96. Kufe, D.: Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol. Therap. 8, 1197–1203 (2009)
97. Vajaria, B.N., Patel, K.R., Begum, R., Patel, P.S.: Sialylation: an avenue to target cancer cells. Pathol. Oncol. Res. J. 22, 443–447 (2016)
98. Brown, J.R., Crawford, B.E., Esko, J.D.: Glycan antagonists and inhibitors: a fount for drug discovery. Crit. Rev. Biochem. Mol. Biol. 42, 481–515 (2007)
99. Rillahan, C.D., Antonopoulos, A., Lefort, C.T., Sonon, R., Azadi, P., Ley, K., et al.: Global metabolic inhibitors of sialyl and fucosyltransferases remodel the glycome. Nat. Chem. Biol. 8, 661–668 (2012)
100. Okeley, N.M., Alley, S.C., Andersen, M.E., Boursalian, T.E., Burke, P.J., Emmerton, K.M., et al.: Development of orally active inhibitors of protein and cellular fucosylation. PNAS. 110, 5404–5409 (2013)